{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-048252","form_type":"8-K","ticker":"ELAB","cik":"0001840563","company_name":"PMGC Holdings Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.091748+00:00","generated_at":"2026-05-15T03:08:14.258324+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"PMGC subsidiary NorthStrive files U.S. patent for EL-22 muscle preservation in humans","bullets":["New U.S. patent application (No. 19/655,160) covers EL-22 as a formulated pharmaceutical product for muscle loss.","EL-22 uses myostatin-engineered probiotic technology targeting sarcopenia, disuse atrophy, and neurological disorders.","The patent includes dosing regimens and formulations; potential use with GLP-1 receptor agonist weight loss treatments.","This filing expands NorthStrive's IP strategy for muscle health therapeutics across pharmaceutical and adjacent markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-048252","json":"https://secwatch.observer/filing/0001213900-26-048252.json","markdown":"https://secwatch.observer/filing/0001213900-26-048252.md","text":"https://secwatch.observer/filing/0001213900-26-048252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026048252/0001213900-26-048252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026048252/ea0287845-8k_pmgc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:08:14.258324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}